T Schnitzer, M Pueyo, H Deckx, E van der Aar, K Bernard, S Hatch, M van der Stoep, S Grankov, D Phung, O Imbert, D Chimits, K Muller, M C Hochberg, H Bliddal, W Wirth, F Eckstein, P G Conaghan
OBJECTIVE: To evaluate the efficacy and safety of the anti-catabolic ADAMTS-5 inhibitor S201086/GLPG1972 for the treatment of symptomatic knee osteoarthritis. DESIGN: ROCCELLA (NCT03595618) was a randomized, double-blind, placebo-controlled, dose-ranging, phase 2 trial in adults (aged 40-75 years) with knee osteoarthritis. Participants had moderate-to-severe pain in the target knee, Kellgren-Lawrence grade 2 or 3 and Osteoarthritis Research Society International joint space narrowing (grade 1 or 2)...
April 12, 2023: Osteoarthritis and Cartilage